Home › Acute Myeloid Leukemia › New York › Rochester
Acute Myeloid Leukemia clinical trials in Rochester, NY
16 studies for Acute Myeloid Leukemia are looking for participants at sites in and around Rochester (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- Rochester General Hospital, Rochester
- University of Rochester, Rochester
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- University of Rochester, Rochester
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RecruitingPhase 3
- University of Rochester Medical Center, Rochester
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- University of Rochester, Rochester
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- University of Rochester, Rochester
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- University of Rochester, Rochester
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RecruitingPhase 3
- University of Rochester, Rochester
A Telehealth Advance Care Planning Intervention
Recruiting
- University of Rochester, Rochester
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- Wilmot Cancer Institute, University of Rochester, Rochester
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
RecruitingPhase 3
- University of Rochester Medical Center (URMC), Rochester
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Strong Memorial Hospital/University of Rochester, Rochester
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
Recruiting
- University of Rochester Medical Center, Rochester
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
RecruitingEarly phase 1
- Wilmot Cancer Institute, University of Rochester, Rochester
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
RecruitingPhase 1/2
- The University of Rochester, Rochester
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
RecruitingObservational study
- University of Rochester Medical Center, Rochester
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
RecruitingHealthy volunteers welcome
- University of Rochester, Rochester
About Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
More about Acute Myeloid Leukemia on MedlinePlus
Acute Myeloid Leukemia trials in other cities
- Houston, TX85 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Seattle, WA41 studies
- Baldwin Park, CA40 studies
- Columbus, OH35 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Atlanta, GA31 studies
- Tampa, FL29 studies
- Chicago, IL26 studies
- Portland, OR25 studies
Other studies in Rochester
- Lung Cancer15 studies
- Breast Cancer15 studies
- Cancer (all types)14 studies
- Obesity14 studies
- Overweight13 studies
- Non-Small Cell Lung Cancer13 studies
- Prostate Cancer10 studies
- Metastatic Cancer8 studies
- Multiple Myeloma8 studies
- Bladder Cancer7 studies
- Myotonic Dystrophy7 studies
- Pancreatic Cancer7 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.